Monoclonal antibodies for the treatment of osteoporosis

Expert Opinion on Biological Therapy

Volumn 13, Issue 2, 2013, Pages 183-196

  Lewiecki, E Michael ^a  

^a NEW MEXICO CLINICAL RESEARCH AND OSTEOPOROSIS CENTER   (United States)

Author keywords

AMG 785 CDP7851; denosumab; DKK1; osteoporosis; RANK; RANKL; sclerostin

Indexed keywords

ABLYNX; ALENDRONIC ACID; ALX 0141; BHQ 880; BLOSOZUMAB; CALCIUM; COLONY STIMULATING FACTOR 1; DENOSUMAB; FIBROBLAST GROWTH FACTOR 23; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MONOCLONAL ANTIBODY; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; PARATHYROID HORMONE[1-34]; ROMOSOZUMAB; SCL ABI; SCLEROSTIN; UNCLASSIFIED DRUG; VITAMIN D;

ADVERSE OUTCOME; ARTHRALGIA; BINDING AFFINITY; BIOSYNTHESIS; BONE REMODELING; CARDIOVASCULAR RISK; CELLULITIS; CEREBROVASCULAR ACCIDENT; DIZZINESS; DOSE RESPONSE; DRUG BINDING; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ECZEMA; ERYTHEMA; FRACTURE; FRACTURE HEALING; FRACTURE NONUNION; HEADACHE; HEART ATRIUM FIBRILLATION; HEPATITIS; HUMAN; HYPOCALCEMIA; INFECTION; INJECTION SITE REACTION; LEUKOCYTE COUNT; LYMPHOCYTE COUNT; NEOPLASM; NONHUMAN; OSTEOBLAST; OSTEOCLAST ACTIVITY; OSTEOLYSIS; OSTEOPOROSIS; POSTMENOPAUSE; PROTEIN EXPRESSION; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; TRABECULAR BONE; UNSPECIFIED SIDE EFFECT;

ANTIBODIES, MONOCLONAL; BONE MORPHOGENETIC PROTEINS; BONE REMODELING; FRACTURE HEALING; GENETIC MARKERS; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; OSTEOPOROSIS; RANK LIGAND;

EID: 84872188393     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.2012.740006     Document Type: Review

References (97)

1. Cooper C, Campion G, Melton LJ III. Hip fractures in the elderly: a world-wide projection. Osteoporos Int 1992;2(6):285-9
2. Klibanski A, Adams-Campbell L, Bassford T, et al. Osteoporosis prevention, diagnosis, and therapy. JAMA 2001;285(6):785-94
3. Melton LJ III, Chrischilles EA, Cooper C, et al. Perspective. How many women have osteoporosis? J Bone Miner Res 1992;7(9):1005-10
4. Center JR, Nguyen TV, Schneider D, et al. Mortality after all major types of osteoporotic fracture in men and women: an observational study. Lancet 1999;353(9156):878-82 (Pubitemid 29126875)
5. Cooper C. The crippling consequences of fractures and their impact on quality of life. Am J Med 1997;103(2A):12S-9S (Pubitemid 27386437)
6. World Health Organisation. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. WHO; Geneva, Switzerland: 1994
7. Baim S, Binkley N, Bilezikian JP, et al. Official Positions of the International Society for Clinical Densitometry and executive summary of the 2007 ISCD Position Development Conference. J Clin Densitom 2008;11(1):75-91
8. World Health Organization: FRAX WHO Fracture Risk Assessment Tool. Available from: http://www.shef.ac.uk/FRAX/[Accessed October 2012]
9. Kanis JA. On behalf of the World Health Organization Scientific Group. Assessment of osteoporosis at the primary health-care level. Technical Report. World Health Organization Collaborating Centre for Metabolic Bone Diseases; University of Sheffield, UK: Printed by the University of Sheffield 2007
10. Wainwright SA, Marshall LM, Ensrud KE, et al. Hip fracture in women without osteoporosis. J Clin Endocrinol Metab 2005;90(5):2787-93 (Pubitemid 40686325)
11. National Osteoporosis Foundation. Clinician's guide to prevention and treatment of osteoporosis. National Osteoporosis Foundation; Washington, DC: 2008
12. Kanis JA, Burlet N, Cooper C, et al. European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int 2008;19(4):399-428
13. Fujiwara S, Nakamura T, Orimo H, et al. Development and application of a Japanese model of the WHO fracture risk assessment tool (FRAX). Osteoporos Int 2008;19(4):429-34
14. Siminoski K, Leslie WD, Frame H, et al. Recommendations for bone mineral density reporting in Canada: a shift to absolute fracture risk assessment. J Clin Densitom 2007;10(2):120-3 (Pubitemid 46680553)
15. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. JAMA 2002;288:321-33
16. Anderson GL, Limacher M, Assaf AR, et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 2004;291(14):1701-12 (Pubitemid 38489892)
17. Liberman UA, Weiss SR, Broll J, et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. N Engl J Med 1995;333:1437-43
18. Black DM, Cummings SR, Karpf DB, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet 1996;348:1535-41 (Pubitemid 26411651)
19. Cummings SR, Black DM, Thompson DE, et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures - Results from the fracture intervention trial. JAMA 1998;280(24):2077-82 (Pubitemid 29014065)
20. McClung MR, Geusens P, Miller PD, et al. Effect of risedronate on the risk of hip fracture in elderly women. N Engl J Med 2001;344:333-40 (Pubitemid 32107641)
21. Reginster J-Y, Minne HW, Sorensen OH, et al. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Osteoporos Int 2000;11:83-91 (Pubitemid 30099515)
22. Harris ST, Watts NB, Genant HK, et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. JAMA 1999;282(14):1344-52 (Pubitemid 29483192)
23. Chesnut III CH, Skag A, Christiansen C, et al. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res 2004;19(8):1241-9 (Pubitemid 41094364)
24. Black DM, Delmas PD, Eastell R, et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 2007;356(18):1809-22 (Pubitemid 46698462)
25. Lyles KW, Colon-Emeric CS, Magaziner JS, et al. Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med 2007;357(18):1799-809 (Pubitemid 350044800)
26. Chesnut CH III, Silverman S, Andriano K, et al. A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. PROOF Study Group. Am J Med 2000;109(4):267-76
27. Reginster JY, Seeman E, De Vernejoul MC, et al. Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: treatment of Peripheral Osteoporosis (TROPOS) study. J Clin Endocrinol Metab 2005;90(5):2816-22 (Pubitemid 40686329)
28. Meunier PJ, Roux C, Seeman E, et al. The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med 2004;350(5):459-68 (Pubitemid 38133766)
29. Ettinger B, Black DM, Mitlak BH, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene - Results from a 3-year randomized clinical trial. JAMA 1999;282(7):637-44
30. Silverman SL, Christiansen C, Genant HK, et al. Efficacy of bazedoxifene in reducing new vertebral fracture risk in postmenopausal women with osteoporosis: results from a 3-year, randomized, placebo-, and active-controlled clinical trial. J Bone Miner Res 2008;23(12):1923-34
31. Cummings SR, Eastell R, Ensrud K, et al. The effects of lasofoxifene on fractures and breast cancer: 3-year results from the PEARL trial. J Bone Miner Res 2008;23(Suppl 1):S81
32. Neer RM, Arnaud CD, Zanchetta JR, et al. Effect of parathyroid hormone (1- 34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001;344:1434-41 (Pubitemid 32402100)
33. Greenspan SL, Bone HG, Ettinger MP, et al. Effect of recombinant human parathyroid hormone (1-84) on vertebral fracture and bone mineral density in postmenopausal women with osteoporosis: a randomized trial. Ann Intern Med 2007;146(5):326-39 (Pubitemid 351650593)
34. Cummings SR, San Martin J, McClung MR, et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 2009;361(8):756-64 In the Phase III FREEDOM registration trail of denosumab, there was a reduction in the risk of vertebral fractures, hip fractures, and nonvertebral fractures
35. Curtis JR, Carbone L, Cheng H, et al. Longitudinal trends in use of bone mass measurement among older Americans, 1999-2005. J Bone Miner Res 2008;23(7):1061-7
36. Foley KA, Foster SA, Meadows ES, et al. Assessment of the clinical management of fragility fractures and implications for the new HEDIS osteoporosis measure. Med Care 2007;45(9):902-6
37. McCombs JS, Thiebaud P, Laughlin-Miley C, Shi J. Compliance with drug therapies for the treatment and prevention of osteoporosis. Maturitas 2004;48(3):271-87 (Pubitemid 38781153)
38. Caro JJ, Ishak KJ, Huybrechts KF, et al. The impact of compliance with osteoporosis therapy on fracture rates in actual practice. Osteoporos Int 2004;15(12):1003-8 (Pubitemid 40064656)
39. Guntur AR, Rosen CJ. Bone as an endocrine organ. Endocr Pract 2012;1-15; Epub ahead of print
40. Karsenty G, Oury F. Biology without walls: the novel endocrinology of bone. Annu Rev Physiol 2012;74:87-104
41. Lewiecki EM. Combination therapy: the Holy Grail for the treatment of postmenopausal osteoporosis? Curr Med Res Opin 2011;27(7):1493-7
42. Theoleyre S, Wittrant Y, Tat SK, et al. The molecular triad OPG/RANK/RANKL: involvement in the orchestration of pathophysiological bone remodeling. Cytokine Growth Factor Rev 2004;15(6):457-74
43. Kearns AE, Khosla S, Kostenuik PJ. Receptor activator of nuclear factor kappaB ligand and osteoprotegerin regulation of bone remodeling in health and disease. Endocr Rev 2008;29(2):155-92 (Pubitemid 351519689)
44. Zhao H, Kitaura H, Sands MS, et al. Critical role of beta3 integrin in experimental postmenopausal osteoporosis. J Bone Miner Res 2005;20(12):2116-23 (Pubitemid 41698775)
45. Zuo C, Huang Y, Bajis R, et al. Osteoblastogenesis regulation signals in bone remodeling. Osteoporos Int 2012;23(6):1653-63
46. Yadav VK, Ryu JH, Suda N, et al. Lrp5 controls bone formation by inhibiting serotonin synthesis in the duodenum. Cell 2008;135(5):825-37
47. Oury F, Yadav VK, Wang Y, et al. CREB mediates brain serotonin regulation of bone mass through its expression in ventromedial hypothalamic neurons. Genes Dev 2010;24(20):2330-42
48. van Staa TP. The pathogenesis, epidemiology and management of glucocorticoid-induced osteoporosis. Calcif Tissue Int 2006;79(3):129-37 (Pubitemid 44440440)
49. Donovan MA, Dempster D, Zhou H, et al. Low bone formation in premenopausal women with idiopathic osteoporosis. J Clin Endocrinol Metab 2005;90(6):3331-6 (Pubitemid 41014294)
50. Marie PJ, Kassem M. Osteoblasts in osteoporosis: past, emerging, and future anabolic targets. Eur J Endocrinol 2011;165(1):1-10
51. Bonewald LF. Chapter 4. Osteocytes. American Society for Bone and Mineral Research; Washington, DC: 2008. p. 22-7
52. Amgen, inc. Prolia(R) Prescribing Information. Available from: http://pi.amgen.com/united-states/xgeva/xgeva-pi.pdf [Accessed August 2012]
53. Amgen, inc. Xgeva(R) Prescribing Information. Available from: http://pi.amgen.com/united-states/xgeva/xgeva-pi.pdf [Accessed August 2012]
54. Bekker PJ, Holloway DL, Rasmussen AS, et al. A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women. J Bone Miner Res 2004;19(7):1059-66 (Pubitemid 41110556)
55. McClung MR, Lewiecki EM, Cohen SB, et al. Denosumab in postmenopausal women with low bone mineral density. N Engl J Med 2006;354(8):821-31 (Pubitemid 43290920)
56. Lewiecki EM, Miller PD, McClung MR, et al. Two-year treatment with denosumab (AMG 162) in a randomized phase 2 study of postmenopausal women with low bone mineral density. J Bone Miner Res 2007;22:1832-41 (Pubitemid 351229299)
57. Miller PD, Bolognese MA, Lewiecki EM, et al. Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial. Bone 2008;43(2):222-9
58. Miller PD, Wagman RB, Peacock M, et al. Effect of denosumab on bone mineral density and biochemical markers of bone turnover: six-year results of a phase 2 clinical trial. J Clin Endocrinol Metab 2011;96(2):394-402
59. McClung MR, Lewiecki EM, Geller ML, et al. Effect of denosumab on bone mineral density and biochemical markers of bone turnover: 8-year results of a phase 2 clinical trial. Osteoporos Int 2012; [Epub ahead of print] .. Eight years of continuous treatment with denosumab is reported in this extension of a Phase II trial
60. Papapoulos S, Chapurlat R, Libanati C, et al. Five years of denosumab exposure in women with postmenopausal osteoporosis: results from the first two years of the FREEDOM extension. J Bone Miner Res 2012;27(3):694-701 .. Five years of continuous treatment with denosumab is reported in this extension of FREEDOM
61. Brown JP, Bone HG, Chapurlat R, et al. Six years of denosumab treatment in postmenopausal women with osteoporosis: results from the the first three years of the FREEDOM extension. Arthritis Rheum 2011;63(12):4044-4
62. Bone HG, Bolognese MA, Yuen CK, et al. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women. J Clin Endocrinol Metab 2008;93(6):2149-57 (Pubitemid 351831529)
63. Brown JP, Prince RL, Deal C, et al. Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded, phase 3 trial. J Bone Miner Res 2009;24(1):153-61
64. Kendler DL, Roux C, Benhamou CL, et al. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy. J Bone Miner Res 2010;25(1):72-81
65. Orwoll E, Teglbjaerg CS, Langdahl BL, et al. A randomized, placebo-controlled study of the effects of denosumab for the treatment of men with low bone mineral density. J Clin Endocrinol Metab 2012;97(9):3161-9
66. Leder B, Uihlein A, Neer R, et al. The effects of combined denosumab and teriparatide administration on bone mineral density in postmenopausal women: the DATA (Denosumab And Teriparatide Administration) study. J Bone Miner Res 2012;27(Suppl 1):S31
67. Black DM, Greenspan SL, Ensrud KE, et al. The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N Engl J Med 2003;349(13):1207-14
68. Miller P, Bolognese M, Lewiecki EM, et al. Effect of denosumab on bone mineral density and bone turnover markers: 48-month results. J Bone Miner Res 2007;22(Suppl 1):S58
69. Amgen Inc. Prolia-(denosumab) injection important safety information. Available from: http://pi.amgen.com/united-states/prolia/prolia-isi.pdf [Accessed August 2012]
70. Brown J, Wagman R, Dempster D, et al. Effects of 5 years of denosumab on bone histology and histomorphometry: the FREEDOM study extension. J Bone Miner Res 2012;27(Suppl 1):S44-4
71. Holz JB. Safety, pharmacokinetics and efficacy of anti-RANKL Nanobody(R) ALX-0141 in healthy postmenopausal women. Available from: http://www.ablynx.com/ wp-content/uploads/2011/05/2011-05-27-ALX-0141-EULAR-final.pdf [Accessed August 2012]
72. Hsu YH, Chen WY, Chan CH, et al. Anti-IL-20 monoclonal antibody inhibits the differentiation of osteoclasts and protects against osteoporotic bone loss. J Exp Med 2011;208(9):1849-61
73. Veverka V, Henry AJ, Slocombe PM, et al. Characterization of the structural features and interactions of sclerostin: molecular insight into a key regulator of Wnt-mediated bone formation. J Biol Chem 2009;284(16):10890-900
74. Li X, Ominsky MS, Warmington KS, et al. Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoporosis. J Bone Miner Res 2009;24(4):578-88
75. Ominsky MS, Vlasseros F, Jolette J, et al. Two doses of sclerostin antibody in cynomolgus monkeys increases bone formation, bone mineral density, and bone strength. J Bone Miner Res 2010;25(5):948-59
76. Agholme F, Li X, Isaksson H, et al. Sclerostin antibody treatment enhances metaphyseal bone healing in rats. J Bone Miner Res 2010;25(11):2412-18
77. Li C, Li X, Xiang J, et al. Systemic treatment with a sclerostin monoclonal antibody enhances fracture healing in the rat femoral closed fracture model. J Bone Miner Res 2009;24(Suppl 1):S352-S353. Available from: http://www.asbmr.org/Meetings/AnnualMeeting/AbstractDetail.aspx? Aid=86bc90c6-c865-462c-8174- e3c1b1029b63
78. Ominsky M, Samadfan R, Jolette J, et al. Sclerostin monoclonal antibody stimulates bone formation and improves the strength and density of the fracture callus and lumbar spine in a primate fibular osteotomy model. J Bone Miner Res 2009;24(Suppl 1):S89-S90. Available from: http://www.asbmr.org/Meetings/ AnnualMeeting/AbstractDetail. aspx?aid169908cb-Ad5c-4ef9-A499- be570135fa1d
79. Padhi D, Jang G, Stouch B, et al. Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody. J Bone Miner Res 2011;26(1):19-26 This is the first study of AMG 785 in humans, supporting continued development of this agent for use in postmenopausal women with osteoporosis.
80. McClung MR, Grauer A, Boonen S, et al. Inhibition of sclerostin with AMG 785 in postmenopausal women with low bone mineral density: phase 2 trial results. J Bone Miner Res 2012;27(Suppl 1):S8
81. McColm J, Womack T, Hu L, et al. Blosozumab, a humanized monoclonal antibody against sclerostin, demonstrated anabolic effects on bone in postmenopausal women. J Bone Miner Res 2012;27(Suppl 1):S9
82. Idolazzi L, Mahamid H, Povino MR, et al. Sclerostin and DKK1 in postmenopausal osteoporosis treated with denosumab. J Bone Miner Res 2012;27(Suppl 1):S329
83. Ke HZ, Richards WG, Li X, Ominsky MS. Sclerostin and dickkopf-1 as therapeutic targets in bone diseases. Endocr Rev 2012;33(5):747-83
84. Glantschnig H, Scott K, Hampton R, et al. A rate-limiting role for DKK1 in bone formation and the remediation of bone loss in mouse and primate models of postmenopausal osteoporosis by an experimental therapeutic antibody. J Pharmacol Exp Ther 2011;338(2):568-78
85. Tian E, Zhan F, Walker R, et al. The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. N Engl J Med 2003;349(26):2483-94 (Pubitemid 38010074)
86. Fulciniti M, Tassone P, Hideshima T, et al. Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myeloma. Blood 2009;114(2):371-9
87. Goldhahn J, Feron JM, Kanis J, et al. Implications for fracture healing of current and new osteoporosis treatments: an ESCEO consensus paper. Calcif Tissue Int 2012;90(5):343-53
88. Gerstenfeld LC, Sacks DJ, Pelis M, et al. Comparison of Effects of the Bisphosphonate Alendronate Versus the RANKL Inhibitor Denosumab on Murine Fracture Healing. J Bone Miner Res 2009;24(2):196-208
89. Adami S, Libanati C, Adachi J, et al. Denosumab administration is not associated with fracture healing complications in postmenopausal women with osteoporosis: results from the3 FREEDOM trial. J Bone Miner Res 2012;25(Suppl 1):S478
90. Kohler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 1975;256(5517):495-7
91. Buss NA, Henderson SJ, McFarlane M, et al. Monoclonal antibody therapeutics: history and future. Curr Opin Pharmacol 2012;12(5):615-22
92. Morrison SL, Johnson MJ, Herzenberg LA, Oi VT. Chimeric human antibody molecules: mouse antigen-binding domains with human constant region domains. Proc Natl Acad Sci USA 1984;81(21):6851-4
93. Baker MP, Reynolds HM, Lumicisi B, Bryson CJ. Immunogenicity of protein therapeutics: the key causes, consequences and challenges. Self Nonself 2010;1(4):314-22
94. Deng R, Jin F, Prabhu S, Iyer S. Monoclonal antibodies: what are the pharmacokinetic and pharmacodynamic considerations for drug development? Expert Opin Drug Metab Toxicol 2012;8(2):141-60
95. Lewiecki EM. New targets for intervention in the treatment of postmenopausal osteoporosis. Nat Rev Rheumatol 2011;7(11):631-8
96. Josse RJ. The role of RANK/RANKL/OPG pathway in bone loss: new insights. Available from: http://www.healthplexus. net/files/content/2009/CGS/Josse. pdf#view=fitV&pagemode=thumbs [Accessed September 2012]
97. Mason JJ, Williams BO. SOST and DKK: antagonists of LRP family signaling as targets for treating bone disease. J Osteoporos 2010;2010:1-9